Role and evolution of therapeutic options

Osteoporosis International

Volumn 6, Issue SUPPL. 2, 1996, Pages 16-20

  Keen, R W ^a   Spector, T D ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; FLUORIDE; IPRIFLAVONE; PARATHYROID HORMONE; VITAMIN D;

ACUPUNCTURE; ANALGESIA; CONFERENCE PAPER; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; TRANSCUTANEOUS NERVE STIMULATION;

EID: 0029760906     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf01625237     Document Type: Conference Paper

References (29)

1. Lees B, Molleson T, Arnett TR, Stevenson JC. Differences in proximal femur bone density over two centuries Lancet 1993;341:673-5.
2. Kanis JA. The incidence of hip fracture in Europe. Osteoporosis Int 1993;3 (Suppl 1):S10-5.
3. Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323:878-83.
4. Reid IA, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmeaopausal women. N Engl J Med 1993;328:460-4.
5. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124-8.
6. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:370-6.
7. Tilyard MW, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-62.
8. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fracture in elderly women. BMJ 1994;308:1081-2.
9. Albrisht F, Smith PH, Richardson AM. Postmenopausal osteoporosis. JAMA 1941;116:2465-74.
10. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980;2:1151-4.
11. Lindsay R, Hart DM, Purdie P, et al. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med 1978;54:193-5.
12. Christiansen C, Riis BJ 17β-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990;71:836-41.
13. Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
14. Steinberg KK, Smith SJ, Thacker SB, Stoup DF. Breast cancer risk and duration of estrogen use: the role of the study design in meta-analysis. Epidemiology 1994;5:415-21.
15. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;322:1589-93.
16. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994;4:314-9.
17. Hassager C, Podenphant J, Riis BJ, et al. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. Metabolism 1989;38:238-42.
18. Overgard K, Hansen MA, Jensen SB, Christiansen C. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ 1992;305:556-61.
19. Mamelle M, Meunier PJ, Dusan R, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;2:361-5.
20. Buckle RM. Three-year study of sodium fluoride treatment on vertebral fracture incidence in osteoporosis. J Bone Miner Res 1989; 4(Suppl 1): S186.
21. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
22. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Intern Med 1995;123:401-8.
23. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
24. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:557-67.
25. Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989;2:1469-71.
26. Libermann UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
27. Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980;280:1340-4.
28. Slovik DM, Neer RM, Potts JT Jr. Short-term effects of synthetic human parathyroid hormone (1-34) administration on bone mineral metabolism in osteoporotic patients. J Clin Invest 1981;68:1261-71.
29. Brandi ML. New treatment strategies: ipriflavone, strontium, vitamin D metabolites and analogs. Am J Med 1993; 95(Suppl 5A):69S-74S.